SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX) a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that Evan M. Levine,
ADVENTRX's chief executive officer, is scheduled to present at the Acumen
BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte
Carlo. Mr. Levine is scheduled to present on Tuesday, May 15, 2007 at 12:55
p.m. Central European Summer Time (6:55 a.m. Eastern Daylight Time). The
conference takes place May 14 - 15, 2007.
The presentation will be webcast live and available for replay via the
"Investors" section of the Company's web site at http://www.adventrx.com
under "Events." The webcast will be made available for replay for 14 days
and can be accessed through the same link.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: uncertainties inherent in the drug development process; the
timing and success of clinical trials; the validity of research results;
the receipt of necessary approvals from the FDA and other regulatory
agencies; and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov. ADVENTRX does not intend
to update any forward-looking statement, including as set forth in this
press release, to reflect events or circumstances arising after the date on
which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/comp/920134.html /
CONTACT:
Investors, Ioana C. Hone of ADVENTRX
Pharmaceuticals, +1-858-552-0866; or Media, Edie DeVine of
WeissComm Partners, +1-415-946-1081, for ADVENTRX Pharmaceuticals
|
